CD4+ Cytotoxic T Cell

A CD4⁺ cytotoxic T cell (CD4⁺ CTL) is a terminally differentiated effector subset of MHC Class II-restricted CD4⁺ T lymphocytes that downregulates the helper-lineage master regulator ThPOK (ZBTB7B), upregulates the cytotoxic-lineage transcription factors Runx3, Eomesodermin (Eomes), T-bet (TBX21), and Blimp-1 (PRDM1), and acquires the cytolytic granule machinery—perforin, granzymes A, B, H, and K, granulysin, NKG7, and Fas ligand (CD95L)—to directly kill target cells in an MHC Class II-dependent manner. Once dismissed as an in vitro tissue-culture artifact, CD4⁺ CTLs were established by Hilde Cheroutre, Daniel Mucida, Alessandro Sette, Vijayanand Pandurangan, and Kosuke Hashimoto (2013–2022) as an authentic, clonally expanded in vivo effector lineage across chronic viral infections (human cytomegalovirus, Epstein–Barr virus, HIV-1, dengue, and SARS-CoV-2), antitumor immunity (bladder carcinoma and melanoma), double-negative T cell-adjacent mucosal surveillance, and human supercentenarian longevity.

In textbook immunology, mature αβ T cells are partitioned by a division of labor: CD8⁺ CTLs recognize endogenous cytosolic peptides on ubiquitously expressed MHC Class I molecules to directly lyse infected cells, whereas CD4⁺ T cells recognize exogenous endolysosomal peptides on MHC Class II molecules to secrete helper cytokines (IFN-γ, IL-4, IL-17, IL-21) that orchestrate macrophages, B cells, and CD8⁺ T cells.

Why did vertebrate evolution preserve a dedicated MHC Class II-restricted cytotoxic CD4⁺ T-cell pathway? The answer lies in the viral immune-evasion arms race:

• Numerous persistent viruses—including human cytomegalovirus (HCMV) (via glycoproteins US2, US3, US6, and US11), Epstein–Barr virus (EBV), herpes simplex virus, adenoviruses, and HIV-1 (via Nef)—along with many solid tumors selectively downregulate or degrade MHC Class I molecules or block the TAP1/TAP2 peptide transporter to render themselves invisible to classical CD8⁺ CTLs.
• However, during viral replication or inflammatory interferon-gamma (IFN-γ) exposure, infected epithelial cells, endothelial cells, keratinocytes, pneumocytes, and tumor cells upregulate the Class II Transactivator (CIITA) and display viral and tumor neoantigen peptides on HLA-DR, HLA-DP, and HLA-DQ (MHC Class II) molecules, while B-lymphotropic viruses (EBV) and myeloid-tropic viruses (HCMV, HIV-1, and dengue) directly infect constitutive MHC Class II⁺ cells.
• CD4⁺ CTLs exploit this MHC Class II axis to execute direct immunological synapse-mediated perforin/granzyme killing of MHC Class I-deficient infected and malignant cells.

During thymic positive selection, double-positive thymocytes committing to the CD4⁺ helper lineage upregulate the zinc-finger transcription factor ThPOK (encoded by ZBTB7B), which binds silencer elements in the Runx3, Cd8a, Prf1 (perforin), and Gzmb (granzyme B) loci to repress the cytotoxic program. Conversely, CD8⁺ thymocytes upregulate Runx3, which silences Zbtb7b and Cd4 while activating cytolytic genes.

In 2013, Hilde Cheroutre, Daniel Mucida, and colleagues (Nature Immunology) demonstrated that the ThPOK/Runx3 switch remains plastic in mature post-thymic peripheral CD4⁺ T cells:

1. Chronic TCR Stimulation + IL-2, IL-15, and Type I Interferon Signaling: When peripheral naive or T_H1-polarized CD4⁺ T cells experience repeated high-affinity antigen stimulation alongside IL-2 (STAT5), IL-12 (STAT4 → T-bet), and costimulation through OX40 (CD134), 4-1BB (CD137), and CRTAM, they induce Blimp-1 (PRDM1) and Eomesodermin (Eomes).
2. Post-Thymic Silencing of Zbtb7b (ThPOK) and Induction of Runx3: Sustained TCR and T-bet/Blimp-1 signaling activates the proximal silencer of the Zbtb7b gene, extinguishing ThPOK expression and de-repressing Runx3.
3. Activation of the Cytolytic Transcriptome and Surface Phenotype: Together, Runx3, Eomes, and T-bet bind to the promoters of PRF1 (perforin), GZMB (granzyme B), GZMA, GZMH, GNLY (granulysin), NKG7, and FASLG. On the cell surface (Patil et al., 2018), human CD4⁺ CTLs lose CD27 and CD28 (CD4⁺CD27⁻CD28^null), re-express CD45RA⁺ (CD4⁺ T_EMRA), and express the fractalkine receptor CX3CR1⁺, adhesion GPCR GPR56⁺, CD57⁺, KLRG1⁺, CRTAM⁺, and NKG2D⁺. Upon contacting an HLA-DR⁺ target cell, they exocytose perforin, granzyme B, and granulysin to trigger target cell apoptosis.

1. Persistent Herpesviruses (HCMV, EBV), Dengue, and HIV-1: In HCMV-seropositive adults, CD4⁺CD28⁻CX3CR1⁺perforin⁺ CTLs constitute 5% to 20% of circulating CD4⁺ T cells, recognizing glycoprotein gB and pp65 peptides on MHC Class II⁺ endothelial and myeloid cells. Similarly, individuals carrying protective HLA-DRB1 alleles against dengue virus mount an expanded CX3CR1⁺Eomes⁺perforin⁺granzyme B⁺ CD4⁺ CTL response (Weiskopf et al., 2015), and early expansion of HIV-Gag-specific granzyme B⁺perforin⁺ CD4⁺ CTLs predicts lower viral set-points in acute HIV-1 infection.
2. Direct Lysis of MHC Class II⁺ Solid Tumors: In 2020, David Y. Oh, Lawrence Fong, and colleagues (Cell) profiled human bladder carcinomas treated with anti-PD-L1 immune checkpoint inhibitor therapy and discovered that clonally expanded intratumoral CD4⁺GZMB⁺GZMK⁺PRF1⁺ CTLs directly lysed autologous tumor cells in an MHC Class II-restricted manner and predicted clinical response to PD-L1 blockade. Similarly, decade-persisting chimeric antigen receptor T-cell (CAR-T) clones in chronic lymphocytic leukemia survivors adopt a GZMK⁺GZMB⁺PRF1⁺ cytotoxic CD4⁺ CTL state.
3. Senescent Cell Clearance and Supercentenarian Longevity (Hashimoto et al., 2019; Hasegawa et al., 2023): Single-cell RNA-seq and TCR-seq of human supercentenarians (aged ≥110 years) (Hashimoto et al., 2019) revealed that CD4⁺ CTLs expanded from ~2.8% of total CD4⁺ T cells in younger adults to an average of 25.3% (and up to 80%) in supercentenarians via clonal expansion. Mechanistically, aging senescent dermal fibroblasts upregulate HLA-II alongside HCMV glycoprotein B antigens, enabling CD4⁺ CTLs to act as endogenous senolytic lymphocytes that clear senescent cells from aging human tissues (Hasegawa et al., 2023).

How can a CD4⁺ T cell kill a solid tumor cell if MHC Class II is normally expressed on antigen-presenting cells?

Exposure to interferon-gamma (IFN-γ) in an inflamed tumor microenvironment induces the transcription factor CIITA inside epithelial, endothelial, and malignant tumor cells (including melanomas, bladder carcinomas, and colorectal cancers). This inducible HLA-DR/DP/DQ expression allows CD4⁺ CTLs to recognize and lyse tumor cells—including tumors that have lost β₂-microglobulin (B2M) or HLA-I to escape CD8⁺ T cells.

Do CD4⁺ CTLs develop as a separate thymic lineage or differentiate from peripheral helper T cells?

Single-cell TCR repertoire tracking (Patil et al., 2018) proves that human CD4⁺ CTLs differentiate post-thymically in the periphery from conventional naive CD4⁺ T cells and T_H1 precursors sharing identical αβ TCR clonotypes when chronic antigen stimulation and IL-2/IL-12/CRTAM signaling silence ThPOK and induce Runx3 and Eomesodermin.

1. Mucida, D., Husain, M. M., Muroi, S., van Wijk, F., Shinnakasu, R., Naoe, Y., Reis, B. S., Huang, Y., Lambolez, F., Docherty, M., Attinger, A., Shui, J.-W., Kim, G., Lena, C. J., Sakaguchi, S., Miyamoto, C., Wang, P., Atarashi, K., Park, Y., Nakayama, T., Honda, K., Ellmeier, W., Kronenberg, M., Taniuchi, I., & Cheroutre, H. (2013). "Transcriptional reprogramming of mature CD4⁺ helper T cells generates distinct MHC class II–restricted cytotoxic T lymphocytes." Nature Immunology, 14(3), 281–289. https://doi.org/10.1038/ni.2523
2. Patil, V. S., Madrigal, A., Schmiedel, B. J., Clarke, J., O'Rourke, P., de Silva, A. D., Harris, E., Peters, B., Seumois, G., Weiskopf, D., Sette, A., & Vijayanand, P. (2018). "Precursors of human CD4⁺ cytotoxic T lymphocytes identified by single-cell transcriptome analysis." Science Immunology, 3(19), eaan8664. https://doi.org/10.1126/sciimmunol.aan8664
3. Hashimoto, K., Kouno, T., Ikawa, T., Hayatsu, N., Miyajima, Y., Yabukami, H., Terooatea, T., Sasaki, T., Suzuki, T., Valentine, M., Pascarella, G., Okazaki, Y., Suzuki, H., Shin, J. W., Minoda, A., Taniuchi, I., Okano, H., Arai, Y., Hirose, N., & Carninci, P. (2019). "Single-cell transcriptomics reveals expansion of cytotoxic CD4 T cells in supercentenarians." Proceedings of the National Academy of Sciences, 116(48), 24242–24251. https://doi.org/10.1073/pnas.1907883116
4. Oh, D. Y., Kwek, S. S., Raju, S. S., Li, T., McCarthy, E., Chow, E., Aran, D., Ilano, A., Pai, C.-C. S., Rancan, C., Allaire, K., Burra, A., Sun, Y., Spitzer, M. H., Mangul, S., Porten, S., Meng, M. V., Friedlander, T. W., Ye, C. J., & Fong, L. (2020). "Intratumoral CD4⁺ T cells mediate anti-tumor cytotoxicity in human bladder cancer." Cell, 181(7), 1612–1625.e13. https://doi.org/10.1016/j.cell.2020.05.017